Further studies will show whether targeting specifically the expression of AKT1m is a suitable strategy to downregulate AKT1 in breast cancer cells without a complete ablation of the ubiquitously expressed transcripts in normal tissues. This evidence concerns the gene AKT1 and breast cancer.